We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Junshi Biosciences

News List

Junshi, Lilly to Co-develop Antibody Therapies for COVID-19 contractpharma
May 13, 2020
Multiple neutralizing antibodies have been engineered, with the lead asset poised to enter clinical testing in the second quarter.
Eli Lilly, Junshi collaborate to develop antibody therapies for Covid-19 disease pharmaceutical-business-review
May 05, 2020
Eli Lilly has collaborated with Junshi Biosciences for the development of therapeutic antibodies to treat and prevent Covid-19, the disease resulted due to the SARS-CoV-2 novel coronavirus.
Covid-19: Junshi Biosciences, OliX Pharmaceuticals explore drugs pharmaceutical-technology
March 24, 2020
Junshi Biosciences has partnered with the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) to co-develop neutralising antibodies for Covid-19 treatment.
Junshi Biosciences aims for $414M Hong Kong, S.A.R., China IPO: Reuters fiercebiotech
December 28, 2018
China’s Junshi Biosciences may follow in compatriot Innovent Biologics’ footsteps as it tees up to raise $414 million in its Hong Kong, S.A.R., China IPO....

Previous page 1 2 Next page